Yang Yang1, Ya Meng1, M Elizabeth Halloran2,3, Ira M Longini1. 1. Department of Biostatistics and Emerging Pathogens Institute, University of Florida, Gainesville. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle. 3. Department of Biostatistics, University of Washington, Seattle.
Abstract
Background: A recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) was licensed for children aged ≥9 years in a few countries, but the dependence of vaccine efficacy on baseline immunity status and age groups has not been fully characterized. Methods: Combining the 2 phase 3 trials CYD14 and CYD15, we estimated the vaccine efficacy for each of the 4 serotypes of dengue virus (DENV), as well as all serotypes combined, simultaneously stratified by baseline immunity status and age group, while accounting for uncertainty in the baseline immunity status of subjects. Results: Baseline seropositive subjects showed high efficacy for all serotypes: 70.2% (95% confidence interval [CI], 57.4%-80.1%) for dengue serotype 1 (DENV-1), 67.9% (95% CI, 49.9%-82.0%) for DENV-2, 77.5% (95% CI, 64.3%-90.2%) for DENV-3, 89.9% (95% CI, 79.8%-99.9%) for DENV-4, and 75.4% (95% CI, 68.3%-81.6%) overall. In contrast, baseline seronegative subjects showed moderate efficacy against DENV-4 (51.2% [95% CI, 20.0%-72.8%]) but no significant efficacy against other serotypes. Among seropositive children, the overall efficacy tended to increase with age: 35.9% (95% CI, -7.6% to 69.3%) for children ≤5 years old, 65.6% (95% CI, 40.3%-84.2%) for those 6-8 years old, 73.4% (95% CI, 62.6%-82.1%) for those 9-11 years old, and 80.6% (95% CI, 72.9%-87.3%) for those 12 years or older. Conclusions: The CYD-TDV vaccine was highly efficacious for all dengue serotypes among children aged >5 years who have acquired baseline immunity from previous exposure. Increasing vaccine efficacy with age was not fully explained by increasing prevalence of baseline immunity with age.
Background: A recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) was licensed for children aged ≥9 years in a few countries, but the dependence of vaccine efficacy on baseline immunity status and age groups has not been fully characterized. Methods: Combining the 2 phase 3 trials CYD14 and CYD15, we estimated the vaccine efficacy for each of the 4 serotypes of dengue virus (DENV), as well as all serotypes combined, simultaneously stratified by baseline immunity status and age group, while accounting for uncertainty in the baseline immunity status of subjects. Results: Baseline seropositive subjects showed high efficacy for all serotypes: 70.2% (95% confidence interval [CI], 57.4%-80.1%) for dengue serotype 1 (DENV-1), 67.9% (95% CI, 49.9%-82.0%) for DENV-2, 77.5% (95% CI, 64.3%-90.2%) for DENV-3, 89.9% (95% CI, 79.8%-99.9%) for DENV-4, and 75.4% (95% CI, 68.3%-81.6%) overall. In contrast, baseline seronegative subjects showed moderate efficacy against DENV-4 (51.2% [95% CI, 20.0%-72.8%]) but no significant efficacy against other serotypes. Among seropositive children, the overall efficacy tended to increase with age: 35.9% (95% CI, -7.6% to 69.3%) for children ≤5 years old, 65.6% (95% CI, 40.3%-84.2%) for those 6-8 years old, 73.4% (95% CI, 62.6%-82.1%) for those 9-11 years old, and 80.6% (95% CI, 72.9%-87.3%) for those 12 years or older. Conclusions: The CYD-TDV vaccine was highly efficacious for all dengue serotypes among children aged >5 years who have acquired baseline immunity from previous exposure. Increasing vaccine efficacy with age was not fully explained by increasing prevalence of baseline immunity with age.
Authors: Luis Villar; Gustavo Horacio Dayan; José Luis Arredondo-García; Doris Maribel Rivera; Rivaldo Cunha; Carmen Deseda; Humberto Reynales; Maria Selma Costa; Javier Osvaldo Morales-Ramírez; Gabriel Carrasquilla; Luis Carlos Rey; Reynaldo Dietze; Kleber Luz; Enrique Rivas; Maria Consuelo Miranda Montoya; Margarita Cortés Supelano; Betzana Zambrano; Edith Langevin; Mark Boaz; Nadia Tornieporth; Melanie Saville; Fernando Noriega Journal: N Engl J Med Date: 2014-11-03 Impact factor: 91.245
Authors: Sri Rezeki Hadinegoro; Jose Luis Arredondo-García; Maria Rosario Capeding; Carmen Deseda; Tawee Chotpitayasunondh; Reynaldo Dietze; H I Hj Muhammad Ismail; Humberto Reynales; Kriengsak Limkittikul; Doris Maribel Rivera-Medina; Huu Ngoc Tran; Alain Bouckenooghe; Danaya Chansinghakul; Margarita Cortés; Karen Fanouillere; Remi Forrat; Carina Frago; Sophia Gailhardou; Nicholas Jackson; Fernando Noriega; Eric Plennevaux; T Anh Wartel; Betzana Zambrano; Melanie Saville Journal: N Engl J Med Date: 2015-07-27 Impact factor: 91.245
Authors: Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Tim K Tsang; Samson L Ghebremariam; Lionel Gresh; Aubree Gordon; M Elizabeth Halloran; Leah C Katzelnick; Diana Patricia Rojas; Guillermina Kuan; Angel Balmaseda; Jonathan Sugimoto; Eva Harris; Ira M Longini; Yang Yang Journal: Nat Commun Date: 2019-03-18 Impact factor: 14.919
Authors: Carl A B Pearson; Kaja M Abbas; Samuel Clifford; Stefan Flasche; Thomas J Hladish Journal: J R Soc Interface Date: 2019-08-21 Impact factor: 4.118
Authors: Nancy Graham; Phil Eisenhauer; Sean A Diehl; Kristen K Pierce; Stephen S Whitehead; Anna P Durbin; Beth D Kirkpatrick; Alessandro Sette; Daniela Weiskopf; Jonathan E Boyson; Jason W Botten Journal: Front Immunol Date: 2020-03-24 Impact factor: 7.561
Authors: Thomas J Hladish; Carl A B Pearson; Kok Ben Toh; Diana Patricia Rojas; Pablo Manrique-Saide; Gonzalo M Vazquez-Prokopec; M Elizabeth Halloran; Ira M Longini Journal: Proc Natl Acad Sci U S A Date: 2020-01-23 Impact factor: 11.205